G
Garrett Nichols
Researcher at Research Triangle Park
Publications - 9
Citations - 1186
Garrett Nichols is an academic researcher from Research Triangle Park. The author has contributed to research in topics: Dolutegravir & Integrase inhibitor. The author has an hindex of 8, co-authored 9 publications receiving 1026 citations. Previous affiliations of Garrett Nichols include GlaxoSmithKline.
Papers
More filters
Journal ArticleDOI
Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection
Sharon Walmsley,Antonio Antela,Nathan Clumeck,Dan Duiculescu,Andrea Eberhard,Felix Gutieŕrez,Laurent Hocqueloux,Franco Maggiolo,Uriel Sandkovsky,Catherine Granier,Keith A. Pappa,Brian Wynne,Sherene Min,Garrett Nichols +13 more
TL;DR: Dolutegravir plus abacavir-lamivudine had a better safety profile and was more effective through 48 weeks than the regimen with efavirenz-tenofovir DF-emtricitabine, thus meeting the criterion for superiority.
Journal ArticleDOI
Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study
Antonella Castagna,Franco Maggiolo,Giovanni Penco,David Wright,Anthony Mills,Robert M. Grossberg,Jean-Michel Molina,Julie Chas,J. Durant,Santiago Moreno,Manuela Doroana,Mounir Ait-Khaled,Jenny Huang,Sherene Min,Ivy Song,Cindy Vavro,Garrett Nichols,Jane M. Yeo +17 more
TL;DR: DTG 50 mg BID–based therapy was effective in this highly treatment-experienced population with INI-resistant virus, and a strong association between baseline DTG susceptibility and response was demonstrated.
Journal ArticleDOI
48-Week Efficacy and Safety of Dolutegravir Relative to Commonly Used Third Agents in Treatment-Naive HIV-1–Infected Patients: A Systematic Review and Network Meta-Analysis
Dipen Patel,Sonya J. Snedecor,Wing Yu Tang,Lavanya Sudharshan,Jessica Lim,Robert L. Cuffe,Sonia Pulgar,Kim Gilchrist,Rodrigo Refoios Camejo,Jennifer Stephens,Garrett Nichols +10 more
TL;DR: Three clinical trials of DTG have demonstrated comparable or superior efficacy and safety to DRV, RAL, and EFV in HIV-1–infected treatment-naive patients, which suggests DTG is also favorable or comparable to other commonly used third agents (ATV/r, LPV/ r, RPV, and EVG/c).
Journal ArticleDOI
Dolutegravir: clinical and laboratory safety in integrase inhibitor-naive patients.
Lloyd Curtis,Garrett Nichols,C. Stainsby,J. Lim,A. Aylott,Brian Wynne,Andrew Clark,Mark Bloch,G. Maechler,L.. Martin-Carpenter,F Raffi,Sherene Min +11 more
TL;DR: The safety profile for DTG 50 mg once daily in INI-naive individuals was comparable to RAL- and DRV/r-containing regimens and generally favorable compared with EFV-containingregimens.
Journal ArticleDOI
Antiviral activity of dolutegravir in subjects with failure on an integrase inhibitor-based regimen: week 24 phase 3 results from VIKING-3
Garrett Nichols,Anthony Mills,Robert M. Grossberg,Adriano Lazzarin,Franco Maggiolo,Jean-Michel Molina,Gilles Pialoux,David Wright,Mounir Ait-Khaled,J Huang,Cindy Vavro,Brian Wynne,Jane Yeo +12 more
TL;DR: VIKING‐3 aimed to examine efficacy and safety of dolutegravir 50 mg twice daily in patients with resistance to multiple ARV classes, including integrase inhibitors (INI).